Roche, Switzerland
Abbott Laboratories
Johnson & Johnson
Pfizer, USA
Domestic diagnostic reagent key enterprises
Shanghai Fosun Pharmaceutical (Group) Co.
Zhongshan University Dahan Gene Co. Hualan Bioengineering Co. Industry Status, Prospect Chinese diagnostic reagent products on the market at present are mainly in three categories, namely, medical reagents, veterinary reagents and reagents for scientific research. Among them, medical diagnostic reagent kits have the fastest development, the most varieties, the largest consumption, the most manufacturers and the most intense competition. China's economic growth rate in recent years has continued to rank first in the world, coupled with a large population base, therefore, the growing demand for medical diagnostic reagents consumer market has become the focus of public attention. In contrast, the United States, Japan, Germany and other countries, although the market size is still positive growth, but has been close to saturation, replaced by other countries in the Asian region of the emerging market, the average market growth rate of 15% -18%. 2006, China's diagnostic reagent industry sales of about 4.64 billion yuan, an increase of 12% compared with the previous year, is 2.1 times in 2001, China's diagnostic reagent industry has seen rapid development in recent years. This shows that China's diagnostic reagent industry has been developing rapidly in recent years. By the spread of the U.S. subprime mortgage crisis, the global capital market shrinks, and venture capital becomes more cautious. Although the impact of the Chinese market is much lower than that of Europe and the United States, but we can still see that China's venture capital began to slow down. At this time, the diagnostic reagent field of the second round of Kemi successfully raised 16.5 million U.S. dollars of venture capital, undoubtedly presents a special significance. Domestic diagnostic reagent industry, represented by Kemi, as the most rapidly developing sub-industry in the field of medical devices, is receiving stronger attention and pursuit under the background of the new medical reform. In 2009, the implementation of the new health care reform on the demand for disease prevention will bring opportunities for the development of preventive and diagnostic biologics enterprises, "prevention-oriented" diagnostic biologics and biologics with technical and scale advantages of the manufacturers will be prioritized to benefit. In addition, with the comprehensive establishment of the national basic medical system, rural and community health equipment will be greatly strengthened. Future government procurement, will give priority to the procurement of domestic enterprises, especially innovative enterprise products, the domestic in vitro diagnostic industry will usher in a great opportunity for development. China Investment Network 2009-2012 China Diagnostic Reagent Industry Investment Analysis and Prospect Forecast Report Wish to adopt! Thank you.